Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Reproductive genetic testing- PreNatal Diagnosis (PND) and Preimplantation Genetic Diagnosis (PGD)-for CDH1 mutations associated with Hereditary Diffuse Gastric Cancer (HDGC)is available in the UK. This qualitative interview study examined high-risk individuals' (n = 35) views of CDH1 reproductive genetic testing. Interviewees generally regarded reproductive genetic testing as an acceptable form of HDGC risk management. However, some were concerned that their genetic risks required them to plan reproduction and anticipated difficulties communicating this to reproductive partners. Individuals had a preference for PGD over PND because it avoided the need for a termination of pregnancy. However, those who had not yet had children expressed concerns about having to undergo IVF procedures and worries about their effectiveness and the need for embryo selection in PGD. It is suggested that high-risk individuals are provided with access to reproductive genetic counselling.

Original publication




Journal article


Fam Cancer

Publication Date





531 - 535


E-Cadherin (CDH1), Hereditary cancer, Hereditary diffuse gastric cancer (HDGC), Preimplantation genetic diagnosis (PGD), Prenatal diagnosis (PND), Reproductive genetic testing, Adult, Aged, Cadherins, Female, Genetic Predisposition to Disease, Genetic Testing, Health Knowledge, Attitudes, Practice, Humans, Male, Middle Aged, Mutation, Pregnancy, Preimplantation Diagnosis, Stomach Neoplasms